Search results for "Infusions"

showing 10 items of 168 documents

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1985

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. …

AdultMalemedicine.medical_specialtyAdolescentRefractory Period ElectrophysiologicalRefractory periodElectrocardiographyBolus (medicine)PiperidinesInternal medicinemedicineHumansPharmacology (medical)Infusions ParenteralHeart AtriaFlecainideAgedFlecainidemedicine.diagnostic_testbusiness.industryAtrial vulnerabilityEffective refractory periodAtrial fibrillationArrhythmias CardiacMiddle Agedmedicine.diseaseAtrial FlutterAnesthesiaCardiologyFemalebusinessElectrocardiographyAnti-Arrhythmia AgentsAtrial fluttermedicine.drugDrugs
researchProduct

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct

No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patie…

2006

In type 1 diabetic patients, the replacement of subcutaneous insulin infusion by intraperitoneal insulin infusion restores the normal physiological gradient between the portal vein and the peripheral circulation, which is likely to modify HDL metabolism. This stable isotope kinetic study was designed to compare HDL apolipoprotein (apo) AI metabolism in seven type 1 diabetic patients first treated by continuous subcutaneous insulin infusion by an external pump and then 3 months after the beginning of intraperitoneal insulin infusion by an implantable pump. Glycaemic control was comparable under subcutaneous and intraperitoneal insulin infusion (HbA1c=7.34+/-0.94% versus 7.24+/-1.00%, NS). HD…

AdultMalemedicine.medical_specialtyApolipoprotein Bmedicine.medical_treatmentCarbon Compounds InorganicSulfidesAdministration Cutaneouschemistry.chemical_compoundInsulin Infusion SystemsDiabetes mellitusInternal medicinemedicineHumansInsulinInfusions ParenteralPancreatic hormoneType 1 diabetesTriglyceridebiologyApolipoprotein A-Ibusiness.industryCholesterolInsulinMetabolismMiddle Agedmedicine.diseaseKineticsEndocrinologyDiabetes Mellitus Type 1chemistrybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessLipoproteins HDLAtherosclerosis
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study

2009

Damage and dysfunction of the vascular endothelium critically influence clinical outcomes after ischemia and reperfusion (I/R). Brief exposure to organic nitrates can protect the vascular endothelium from I/R injury via a mechanism that is similar to ischemic preconditioning and is independent of hemodynamic changes. The clinical relevance of these protective effects clearly depends on whether they can be sustained over time. Twenty-four healthy (age 25–32) male volunteers were randomized to receive 1) transdermal nitroglycerin (GTN; 0.6 mg/h) administered for 2 h on 1 day only, 2) transdermal GTN for 2 h/day for 7 days, or 3) continuous therapy with transdermal GTN for 7 days. Eight volunt…

AdultMalemedicine.medical_specialtyEndotheliumPhysiologyVasodilator AgentsIschemiaAscorbic AcidAdministration CutaneousAntioxidantsNitroglycerinIn vivoPhysiology (medical)Internal medicinemedicineHumansInfusions Intra-ArterialIschemic PreconditioningNitroglycerinDose-Response Relationship Drugbusiness.industryDrug Tolerancemedicine.diseaseAcetylcholineOrganic nitratesPlethysmographyVascular endotheliummedicine.anatomical_structureReperfusion InjuryAnesthesiaCirculatory systemcardiovascular systemCardiologyIschemic preconditioningEndothelium VascularCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.

1998

Objectives: α-Interferons (α-IFN) have been shown to be effective in the treatment of chronic viral C hepatitis, but their efficacy remains unsatisfactory. Recently natural β-interferon (β-IFN) administered by intravenous infusion has been used successfully. Methods: To evaluate the efficacy and safety of intravenous β-IFN administration we treated 20 patients with histologically proven chronic hepatitis C who were nonresponders to at least two previous courses of α-IFN treatment. All patients received 6 million units (MU) of natural human fibroblast β-IFN by drip infusion, 6 times per wk for 8 wk and were followed up for 6 months after suspension of treatment. Results: Five patients (25%) …

AdultMalemedicine.medical_specialtyGenotypeHepacivirusHepatitis C virusmedicine.medical_treatmentAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyInternal medicinemedicineHumansInfusions IntravenousInterferon alfaHepatitisbiologyHepatologybusiness.industryGastroenterologyInterferon-alphaImmunotherapyInterferon-betaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseSurgeryTreatment OutcomeRNA ViralFemaleViral diseasebusinessViral loadmedicine.drugThe American journal of gastroenterology
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Patients' and relatives' perceptions about intravenous and subcutaneous hydration.

2005

Hydration during palliative care is a controversial topic. Most of the arguments are based on anedoctal reports that have not been substantiated with scientific data. Given that the choice is problematic from a clinical perspective, preferences of patients and family should dictate whether intravenous fluids are administered. The aim of this study was to evaluate patient and family perceptions about hydration and two modes of providing hydration. Fifty-four consecutive patients admitted to an acute pain relief and palliative care unit who required hydration completed a questionnaire regarding their perceptions on hydration and modes of hydration. Similarly, the principal family carer was ch…

AdultMalemedicine.medical_specialtyPalliative carePatientsmedia_common.quotation_subjectInjections SubcutaneousMEDLINEadvanced cancer patientsPatient satisfactionPerceptionmedicineSubcutaneous HydrationHumansFamilyIntensive care medicineFamily carerInfusions Intravenousintravenous and subcutaneous hydrationGeneral Nursingmedia_commonAgedAged 80 and overbusiness.industryPalliative CareMiddle AgedSubcutaneous routeAnesthesiology and Pain MedicinePatient SatisfactionPatients' and relatives' perceptionFluid TherapyFemaleNeurology (clinical)businessIntravenous routeJournal of pain and symptom management
researchProduct